We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-25.23%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$680M
AUM Growth
-$201M
Cap. Flow
+$49.3M
Cap. Flow %
7.24%
Top 10 Hldgs %
94.35%
Holding
15
New
1
Increased
11
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$17.2M
2
MRUS
Merus
MRUS
+$9.78M
3
BPMC
Blueprint Medicines
BPMC
+$9.76M
4
ARVN icon
Arvinas
ARVN
+$8.98M
5
QURE icon
uniQure
QURE
+$3.93M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 50.35%
2 Miscellaneous 49.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$180M 26.42%
+2,000,000
New +$185M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$792B
$158M 23.23%
350,000
-650,000
-65% -$289M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$49.9M 7.34%
781,539
+136,000
+21% +$9.76M
ARWR icon
4
Arrowhead Research
ARWR
$9.33B
$48.2M 7.08%
1,047,440
+347,014
+50% +$17.2M
ARVN icon
5
Arvinas
ARVN
$509M
$46.8M 6.88%
695,247
+131,796
+23% +$8.98M
SPRO icon
6
Spero Therapeutics
SPRO
$72.8M
$45.9M 6.75%
5,281,504
+317,323
+6% +$3.25M
RGNX icon
7
Regenxbio
RGNX
$478M
$37.1M 5.46%
1,118,684
+105,088
+10% +$2.92M
MRUS
8
DELISTED
Merus
MRUS
$33.4M 4.9%
1,261,534
+365,032
+41% +$9.78M
FDMT icon
9
4D Molecular Therapeutics
FDMT
$813M
$26.5M 3.9%
1,755,506
+245,562
+16% +$3.86M
QURE icon
10
uniQure
QURE
$2.66B
$16.3M 2.39%
901,490
+225,284
+33% +$3.93M
AMYT
11
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$13.6M 1.99%
1,640,000
– –
PVLA
12
Palvella Therapeutics
PVLA
$2.1B
$11.2M 1.65%
46,361
+6,404
+16% +$1.68M
ARGX icon
13
argenx
ARGX
$60.2B
$7.57M 1.11%
24,000
+1,800
+8% +$523K
GMAB icon
14
Genmab
GMAB
$21.4B
$6.06M 0.89%
167,500
+40,000
+31% +$1.37M
DNTH icon
15
Dianthus Therapeutics
DNTH
$5.07B
– –
-197,193
Closed -$14M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Aquilo Capital Management held 15 positions worth $680M, down 23% from $882M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Aquilo Capital Management deployed $49.3M of net new capital in Q1 2022, opening 1 new position and adding to 11 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 46% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was Dianthus Therapeutics, an estimated $14M sold.

  • Aquilo Capital Management added most to Arrowhead Research in Q1 2022, an estimated $17.2M increase.
  • Aquilo Capital Management fully exited Dianthus Therapeutics in Q1 2022, selling an estimated $14M.
  • Aquilo Capital Management's ten largest holdings make up 94% of its $680M portfolio in Q1 2022.
  • Aquilo Capital Management opened 1 new position and closed 1 in Q1 2022.
  • Aquilo Capital Management's portfolio value fell 23% quarter-over-quarter to $680M.

Based on Aquilo Capital Management's 13F filing for Q1 2022, filed 16 May 2022.